[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100624175":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":38,"centralContacts":52,"locations":61,"responsibleParty":122,"collaborators":126,"id":130,"slug":131,"hasResults":132,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":132,"sex":138,"minAge":139,"maxAge":33,"enrollmentInfo":140,"targetDuration":33,"studyType":143,"phases":144,"briefSummary":146,"conditions":147,"keywords":150,"overallStatus":63,"whyStopped":33,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":165},{"fullName":5,"class":6},"University Hospital, Geneva","OTHER",[8,13,19,23],{"label":9,"type":6,"description":10,"interventionNames":11},"Nirmatrelvir\u002Fritonavir (nirmatrelvir\u002Fr) 5 days alone","Nirmatrelvir\u002Fr 300mg\u002F100 mg bis in die (twice a day, bid) will be given for 5 days, orally. Nirmatrelvir\u002Fr is a combination of two molecules: nirmatrelvir which is a protease inhibitor (against 3CL) and ritonavir which has a booster role. Nirmatrelvir\u002Fr (marketed by Pfizer under the brand name Paxlovid®) is indicated for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19. Paxlovid® for 5 days is the standard of care.",[12],"Drug: Paxlovid 5 days",{"label":14,"type":15,"description":16,"interventionNames":17},"Nirmatrelvir\u002Fritonavir (nirmatrelvir\u002Fr) 10 days alone","EXPERIMENTAL","Intervention Nirmatrelvir\u002Fr 300mg\u002F100 mg bid will be given for 10 days, orally.",[18],"Drug: Paxlovid 10 days",{"label":20,"type":15,"description":21,"interventionNames":22},"Nirmatrelvir\u002Fritonavir (nirmatrelvir\u002Fr) 5 days + remdesivir single dose","Nirmatrelvir\u002Fr 300mg\u002F100 mg bid will be given for 5 days, orally. Nirmatrelvir\u002Fr is a combination of two molecules: nirmatrelvir which is a protease inhibitor (against 3CL) and ritonavir which has a booster role. Nirmatrelvir\u002Fr (marketed by Pfizer under the brand name Paxlovid®) is indicated for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19. Remdesivir \"flash\", 200mg, intravenous. Remdesivir (marketed by Gilead under de brand name Veklury®) is indicated in patients with pneumonia requiring supplemental oxygen (inpatients), as well as in outpatients who are at increased risk of progressing to severe COVID-19. The mode of action characterize remdesivir as a direct-acting antiviral compound.",[12],{"label":24,"type":15,"description":25,"interventionNames":26},"Nirmatrelvir\u002Fritonavir (nirmatrelvir\u002Fr) 10 days + remdesivir single dose","Nirmatrelvir\u002Fr 300mg\u002F100 mg bid will be given for 10 days, orally. Remdesivir \"flash\", 200mg, intravenous. Remdesivir (marketed by Gilead under de brand name Veklury®) is indicated in patients with pneumonia requiring supplemental oxygen (inpatients), as well as in outpatients who are at increased risk of progressing to severe COVID-19. The mode of action characterize remdesivir as a direct-acting antiviral compound.",[18],[28,34],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"DRUG","Paxlovid 5 days","Nirmatrelvir\u002Fr 300mg\u002F100 mg bid will be given for 5 days, orally. Nirmatrelvir\u002Fr is a combination of two molecules: nirmatrelvir which is a protease inhibitor (against 3CL) and ritonavir which has a booster role. Nirmatrelvir\u002Fr (marketed by Pfizer under the brand name Paxlovid®) is indicated for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19.",[20,9],null,{"type":29,"name":35,"description":36,"armGroupLabels":37,"otherNames":33},"Paxlovid 10 days","Nirmatrelvir\u002Fr 300mg\u002F100 mg bid will be given for 10 days, orally.",[24,14],[39,43,46,49],{"name":40,"affiliation":41,"role":42},"Alexandra Calmy, MD PhD","Hopitaux Universitaires de Genève","PRINCIPAL_INVESTIGATOR",{"name":44,"affiliation":45,"role":42},"Nina Khanna, MD PhD","Basel University Hospital",{"name":47,"affiliation":48,"role":42},"Nicolas Muller, MD PhD","University of Zurich",{"name":50,"affiliation":51,"role":42},"Oriol Manuel, MD PhD","University Hospital CHUV",[53,57],{"name":40,"role":54,"phone":55,"phoneExt":33,"email":56},"CONTACT","+41 22 372 98 12","alexandra.calmy@hug.ch",{"name":58,"role":54,"phone":59,"phoneExt":33,"email":60},"Chiara Fedeli, PhD","+41 (0)22 372 9817","chiara.fedeli@hug.ch",[62,79,92,107],{"facility":45,"status":63,"city":64,"state":64,"zip":65,"country":66,"countryCode":67,"cosmosGeoPoint":68,"geoPoint":73,"contacts":74},"RECRUITING","Basel","4031","Switzerland","CH",{"type":69,"coordinates":70},"Point",[71,72],7.57327,47.55839,{"lat":72,"lon":71},[75],{"name":76,"role":54,"phone":77,"phoneExt":33,"email":78},"Nina Khanna","+41 61 328 73 25","nina.khanna@usb.ch",{"facility":80,"status":63,"city":81,"state":82,"zip":83,"country":66,"countryCode":67,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"Hôpitaux Universitaires de Genève","Geneva","Canton of Geneva","1205",{"type":69,"coordinates":85},[86,87],6.14569,46.20222,{"lat":87,"lon":86},[90],{"name":91,"role":54,"phone":55,"phoneExt":33,"email":56},"Alexandra Calmy",{"facility":93,"status":63,"city":94,"state":95,"zip":96,"country":66,"countryCode":67,"cosmosGeoPoint":97,"geoPoint":101,"contacts":102},"CHUV","Lausanne","Canton of Vaud","10-549",{"type":69,"coordinates":98},[99,100],6.63282,46.516,{"lat":100,"lon":99},[103],{"name":104,"role":54,"phone":105,"phoneExt":33,"email":106},"Oriol Manuel","+41 21 314 3020","oriol.manuel@chuv.ch",{"facility":108,"status":63,"city":109,"state":110,"zip":111,"country":66,"countryCode":67,"cosmosGeoPoint":112,"geoPoint":116,"contacts":117},"University Hospital Zurich","Zurich","Canton of Zurich","8091",{"type":69,"coordinates":113},[114,115],8.55,47.36667,{"lat":115,"lon":114},[118],{"name":119,"role":54,"phone":120,"phoneExt":33,"email":121},"Nicolas Muller","+41 1 255 37 12","nicolas.mueller@usz.ch",{"type":123,"investigatorFullName":124,"investigatorTitle":125,"investigatorAffiliation":5,"oldNameTitle":33,"oldOrganization":33},"SPONSOR_INVESTIGATOR","Calmy Alexandra","Prof",[127],{"name":128,"class":129},"ANRS, Emerging Infectious Diseases","OTHER_GOV","100624175","phase-2-optimisation-of-antiviral-therapy-in-immunocompromised-covid-19-patients-100624175",false,"NCT07406217","OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients","OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial: the SWISS OPTICOV Study","SWISS OPTICOV","Inclusion Criteria:\n\n1. Laboratory confirmed SARS-CoV-2 infection by real time RT-PCR or positive antigenic test (commercialized assay)\n2. Asymptomatic or mild to moderate COVID-19 (WHO progression scale \\\u003C5. Patients receiving oxygen therapy for reasons other than a pulmonary COVID-19 are eligible).\n3. ≥ 16 years of age;\n4. Immunocompromised as defined by ≥ 1 risk factors for severe COVID-19 as assessed by the Federal Office of Public Health (FOPH) list (criteria 5: diseases\u002Ftreatments leading to immune suppression) or other immunosuppression criteria such as:\n\n   * Severe immunosuppression (e.g., human immunodeficiency virus (HIV) infection with CD4 + T cell count \\\u003C350 \u002F μl)\n   * Neutropenia (\\\u003C1000 neutrophils \u002F μl) ≥1 week\n   * Lymphocytopenia (\\\u003C200 lymphocytes\u002Fμl)\n   * On dialysis treatment\n   * Hereditary immunodeficiencies\n   * Intake of drugs which suppress the immune system (e.g. glucocorticoids for a long time \\[an equivalent dose of prednisone \\>20 mg\u002Fday \\> 3 months\\], monoclonal antibodies, cytostatics, biological products, everolimus, mTOR inhibitors etc.) in the last 12 months\n   * Active cancer under cytostatics or targeted therapy known to be immunosuppressive (e.g., platinum salts, cyclophosphamide, anthracyclines, taxanes, 5-fluorouracil, gemcitabine, purine inhibitors, proteasome inhibitors) or associated with hematologic toxicity (neutropenia, lymphopenia), for example sunitinib, imatinib, regorafenib.\n   * Aggressive lymphomas (all types)\n   * Acute lymphatic leukemia\n   * Acute myeloid leukemia\n   * Acute promyelocytic leukemia\n   * T prolymphocytic leukemia\n   * Primary central nervous system lymphoma\n   * Stem cell transplantation\n   * Light chain amyloidosis\n   * Chronic lymphoid leukemia\n   * Multiple myeloma\n   * Sickle cell disease\n   * Bone marrow transplant\n   * Organ transplant\n   * Being on the waiting list for an organ transplant\n5. Willing and able to comply with study requirements and restrictions as described in the informed consent form (ICF)\n6. Enrolled in or a beneficiary of a Social Security program (State Medical Aid (AME) is not a Social Security program) or holders of health insurance.\n7. Participant's or its legal representative's signature of the informed consent form\n\nExclusion Criteria:\n\n1. SARS-CoV-2 PCR ≥30 CT at screening\n2. Hypersensitivity to study drugs (active substance(s) or excipients)\n3. Body weight \\\u003C 40 kg\n4. AST (Aspartate transaminase) and\u002For alanine transaminase (ALT) \\> 5 times the upper limit\n5. Cirrhosis Child-Pugh score C\n6. Is taking or is anticipated to require any prohibited therapies\\*.\n7. Participation in another interventional clinical study with an investigational compound or device, including COVID-19 therapeutics, where the study intervention is performed in the 28 days preceding the inclusion and the 10 days after the inclusion. Investigators of the different clinical studies should agree on participant's inclusion.\n8. Presence of any condition for which, in the opinion of the investigator, participation would not be in participant's best interest or that could prevent, limit, or confound the protocol-specified assessments\n9. Having received antiviral treatments against SARS-CoV-2 in the 14 days before the inclusion with exception of those having received one or two doses of nirmatrevir\u002Fr in the 24h preceding the inclusion in the study.\n10. Pregnant or breastfeeding female","ALL","16 Years",{"count":141,"type":142},256,"ESTIMATED","INTERVENTIONAL",[145],"PHASE2","The overall purpose of the trial is to evaluate the efficacy and safety of possible combination antiviral therapy direct antiviral agents (remdesivir + nirmatrelvir\u002Fr) versus the reference monotherapy (nirmatrelvir\u002Fr alone) and to assess the efficacy and safety of increasing the nirmatrelvir\u002Fr course from 5- to 10 days in immunocompromised patients diagnosed with asymptomatic or mild to moderate Coronavirus Disease 2019 (COVID-19).",[148,149],"COVID-19","Immunodeficiency",[148,151,152,153,154,155],"Immunodepression","SARS-CoV-2","Paxlovid","Veklury","Viral load","2026-02-13",{"date":158,"type":159},"2026-02-18","ACTUAL",{"date":161,"type":159},"2023-04-27",{"date":163,"type":142},"2026-06-30",{"name":124,"class":6},4]